Spots Global Cancer Trial Database for Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Official Title: Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Study ID: NCT05800197

Conditions

Breast Cancer

Neoadjuvant Endocrine Therapy

Interventions

Study Description

Brief Summary: Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.

Detailed Description: Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia. Nonrandomized, retrospective clincal trial Eligible postmenopausal women were treated with tamoxifen 20 mg, exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily before surgery or Eligible premenopausal women were treated with tamoxifen 20 mg, exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily in combination with ovarian suppression before surgery